Effect of a new CCK-receptor antagonist, CR 1409, on pancreatic growth induced by caerulein, CCK-8, bombesin and gastrin-releasing peptide in the rat.
The effect of a peripheral cholecystokinin (CCK)-receptor antagonist, CR 1409, on pancreatic growth has been studied in the rat. 1.8 nmol/kg CCK-8 or caerulein and 3.6 nmol/kg bombesin or gastrin-releasing peptide (GRP) administered subcutaneously 3 times daily for 4 successive days increased pancreatic weight and its content in protein, enzymes and RNA but not in DNA, suggesting cellular hypertrophy. CR 1409 (10 mg/kg) administered intragastrically 30 min prior to peptides prevented pancreatic growth due to CCK-8 or caerulein but not that induced by bombesin and GRP. It is concluded that bombesin and GRP act on the exocrine pancreas directly rather than through the release of CCK.
Hajri
A
A
INSERM Unit 61, Digestive Cell Biology and Physiopathology, Strasbourg, France.
Aprahamian
M
M
Damgé
C
C
D000818:Animals; D001839:Bombesin / Q000494:pharmacology*; D002108:Ceruletide / Q000494:pharmacology*; D019886:Gastrin-Releasing Peptide; D005768:Gastrointestinal Hormones / Q000494:pharmacology*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010179:Pancreas / Q000187:drug effects / Q000254:growth & development*; D010455:Peptides / Q000494:pharmacology; D011377:Proglumide / Q000494:pharmacology / Q000031:analogs & derivatives; D051381:Rats; D011919:Rats, Inbred Strains; D012844:Sincalide / Q000494:pharmacology
D005768:Gastrointestinal Hormones; D010455:Peptides; D019886:Gastrin-Releasing Peptide; D002108:Ceruletide; D011377:Proglumide; C048181:lorglumide; D012844:Sincalide; D001839:Bombesin